CTNNB1 syndrome and neurodevelopmental disorders
Research activity is centered on CTNNB1 syndrome, with attention to the pediatric population affected by this rare neurodevelopmental disorder. The sponsor’s clinical focus includes gene therapy approaches designed for central nervous system delivery.
- CTNNB1-related neurological disease
- pediatric neurogenetic conditions
- rare disease therapeutics
The sponsor’s trial portfolio is directed toward conditions involving impaired brain development and neurological function.
Gene therapy and AAV9-based treatment
The sponsor is actively involved in gene replacement therapy using an AAV9 vector platform, with clinical interest in restoring function in patients with genetically driven disease. This work reflects a focus on molecular medicine and targeted genetic intervention.
- gene replacement therapy
- AAV9 vector
- genetic correction strategies
The therapeutic emphasis is on in vivo genetic treatment for a rare disorder with a defined molecular basis.
Intracerebroventricular administration and central nervous system delivery
Clinical interest extends to intracerebroventricular administration as a route for delivering therapy directly to the central nervous system. This area is relevant to disorders requiring targeted access to the brain and cerebrospinal fluid spaces.
- intracerebroventricular injection
- central nervous system targeting
- cerebrospinal fluid delivery
The sponsor’s research landscape includes therapeutic delivery methods suited to neurological gene therapy.
Safety, tolerability, and preliminary efficacy
Current clinical interest includes assessment of safety, tolerability, and early signs of efficacy in children receiving a genetic therapy for CTNNB1 syndrome. These areas are central to the sponsor’s work in translating experimental genetic medicine into patient-focused care.
- treatment safety
- tolerability assessment
- early efficacy evaluation
The research profile is concentrated on clinical application in rare pediatric neurology.
